Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium Ready to Announce with Confidence?
Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.
Presentation Details
Date: Thursday, July 9, 2026
Time: 2:30 p.m. Eastern Daylight Time
Live Presentation: Available on Kiora's Investor Relations homepage at ir.kiorapharma.com
Replay: Available for 90 days on Kiora's Investor Relations Events page at ir.kiorapharma.com/news-events/events
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed initially for the treatment of retinitis pigmentosa, with potential to expand into choroideremia and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of macular edema due to retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Contact:
investors@kiorapharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303675
Source: Kiora Pharmaceuticals, Inc.
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Kiora Pharmaceuticals, Inc. or all companies in the Biotechnology, Pharmaceuticals industry.
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
2026-07-02 7:00 AM EDT
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
2026-06-18 7:00 AM EDT
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-08 7:00 AM EDT
Oct 24, 2025
If your company files on SEDAR+, it’s time to prepare for the SEDAR+ fee increase 2025, a significant adjustment approved by the Canadian Securities Administrators (CSA).
Economy, Business and Finance
Biotechnology
Chemicals
Pharmaceutical
C.E.O. Interview
Biotechnology
Pharmaceuticals